← 전체 보충제 목록

세이지

Sage

📑 PubMed 36편 🌿 허브

📚 관련 논문 (30편)

1.
Incidence and Nature of Antidepressant Discontinuation Symptoms: A Systematic Review and Meta-Analysis.
JAMA psychiatry 2025 PMID:40632531

1. JAMA Psychiatry. 2025 Sep 1;82(9):896-904. doi: 10.1001/jamapsychiatry.2025.1362. Incidence and Nature of Antidepressant Discontinuation Symptoms: A Systematic Review and Meta-Analysis. Kalfas M(1), Tsapekos D(1), Butler M(2), McCutcheon RA(3)(4)(5), Pillinger T(5)(6), Strawbridge R(1), Bhat

2.
Efficacy and acceptability of long-acting antipsychotics in acutely ill individuals with schizophrenia-spectrum disorders: A systematic review and network meta-analysis.
Psychiatry research 2024 PMID:39173348

2. Psychiatry Res. 2024 Oct;340:116124. doi: 10.1016/j.psychres.2024.116124. Epub 2024 Aug 9. Efficacy and acceptability of long-acting antipsychotics in acutely ill individuals with schizophrenia-spectrum disorders: A systematic review and network meta-analysis. Vita G(1), Pollini D(1), Canozz

3.
Nutraceuticals and phytoceuticals in the treatment of schizophrenia: a systematic review and network meta-analysis "Nutra NMA SCZ".
Molecular psychiatry 2025 PMID:39026098

3. Mol Psychiatry. 2025 Jan;30(1):168-187. doi: 10.1038/s41380-024-02645-y. Epub 2024 Jul 18. Nutraceuticals and phytoceuticals in the treatment of schizophrenia: a systematic review and network meta-analysis "Nutra NMA SCZ". Fornaro M(#)(1), Caiazza C(#)(2), Billeci M(2), Berk M(3)(4)(5)(6)(7),

4.
Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis.
Molecular psychiatry 2022 PMID:35760879

4. Mol Psychiatry. 2022 Sep;27(9):3658-3669. doi: 10.1038/s41380-022-01652-1. Epub 2022 Jun 27. Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis. Medeiros GC(1)(2), Gould TD(2)(3)(4), Prueitt WL(5), Nanavati J(6), Grunebaum MF(7

5.
Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis.
Molecular autism 2022 PMID:35246237

5. Mol Autism. 2022 Mar 4;13(1):10. doi: 10.1186/s13229-022-00488-4. Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis. Siafis S(1), Çıray O(2), Wu H(3), Schneider-Thoma J(3), Bighelli I(3), Krause M(4), Rodolico A(5), C

6.
Association between food insecurity and depression among older adults from low- and middle-income countries.
Depression and anxiety 2021 PMID:33687122

6. Depress Anxiety. 2021 Apr;38(4):439-446. doi: 10.1002/da.23147. Epub 2021 Mar 9. Association between food insecurity and depression among older adults from low- and middle-income countries. Smith L(1), Il Shin J(2), McDermott D(3), Jacob L(4)(5), Barnett Y(6), López-Sánchez GF(7), Veronese N(

7.
Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis.
Molecular autism 2020 PMID:32847616

7. Mol Autism. 2020 Aug 26;11(1):66. doi: 10.1186/s13229-020-00372-z. Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis. Siafis S(1), Çıray O(2), Schneider-Thoma J(3), Bighelli I(3), Krause M(3), Ro

8.
Patient and provider perspectives of Brief Cognitive Behavioral Therapy for Chronic Pain: a qualitative analysis of a pilot randomized controlled trial.
Translational behavioral medicine 2026 PMID:41981856

8. Transl Behav Med. 2026 Jan 7;16(1):ibag011. doi: 10.1093/tbm/ibag011. Patient and provider perspectives of Brief Cognitive Behavioral Therapy for Chronic Pain: a qualitative analysis of a pilot randomized controlled trial. Conrad M(1)(2), Kimber JM(3)(4), Moskal D(5), Pietropaoli VA, King PR J

9.
Fractional BNT162b2 boosters induce durable immune responses after non-mRNA priming in Mongolia: a randomised controlled trial.
Frontiers in immunology 2026 PMID:41948336

9. Front Immunol. 2026 Mar 23;17:1789248. doi: 10.3389/fimmu.2026.1789248. eCollection 2026. Fractional BNT162b2 boosters induce durable immune responses after non-mRNA priming in Mongolia: a randomised controlled trial. Batmunkh T(1), Neal EF(2)(3), Amraa O(1), Mazarakis N(2)(3), Altangerel B(4

10.
Personalized fMRI-Guided TMS Targeting the Threat Neurocircuitry in PTSD: A Randomized Clinical Trial.
The American journal of psychiatry 2026 PMID:41922982

10. Am J Psychiatry. 2026 May 1;183(5):343-354. doi: 10.1176/appi.ajp.20250749. Epub 2026 Apr 2. Personalized fMRI-Guided TMS Targeting the Threat Neurocircuitry in PTSD: A Randomized Clinical Trial. van Rooij SJH(1), Langhinrichsen-Rohling R(1), Minton ST(1), Hinojosa CA(1)(2), Lukemire J(3),

11.
The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis.
Journal of affective disorders 2026 PMID:41881122

11. J Affect Disord. 2026 Aug 1;406:121662. doi: 10.1016/j.jad.2026.121662. Epub 2026 Mar 23. The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis. Goodwin GM(1), Aaronson ST(2), Alvarez O(3), Carhart-Harris R(4), Croal M(5), Feif

12.
Efficacy and safety of brexpiprazole in early-episode schizophrenia: post hoc analysis of Phase 3 clinical trials in adults and adolescents.
Psychiatry research 2026 PMID:41849920

12. Psychiatry Res. 2026 Jun;360:117091. doi: 10.1016/j.psychres.2026.117091. Epub 2026 Mar 12. Efficacy and safety of brexpiprazole in early-episode schizophrenia: post hoc analysis of Phase 3 clinical trials in adults and adolescents. Correll CU(1), Yildirim M(2), Zhang Z(3), Palma AM(3), Pham

13.
Transient frontal spectral events from EEG predict antidepressant response to sertraline in depression.
Journal of psychiatric research 2026 PMID:41849883

13. J Psychiatr Res. 2026 Jun;197:313-320. doi: 10.1016/j.jpsychires.2026.03.010. Epub 2026 Mar 11. Transient frontal spectral events from EEG predict antidepressant response to sertraline in depression. Waller DA(1), Carpenter LL(2), Jones SR(3). Author information: (1)Department of Neuroscien

14.
A Randomized Trial of Vitamin D Supplementation and COVID-19 Clinical Outcomes and Long COVID: The Vitamin D for COVID-19 Trial.
The Journal of nutrition 2026 PMID:41826107

14. J Nutr. 2026 Apr;156(4):101398. doi: 10.1016/j.tjnut.2026.101398. Epub 2026 Mar 12. A Randomized Trial of Vitamin D Supplementation and COVID-19 Clinical Outcomes and Long COVID: The Vitamin D for COVID-19 Trial. Ganmaa D(1), Cook KA(2), Khudyakov P(3), Enkhjargal D(4), Bilegtsaikhan T(5),

15.
Assessing the presence of biasing and non-biasing unblinding in a randomized controlled trial of a home-use tDCS device: An exploratory analysis.
Journal of affective disorders 2026 PMID:41796776

15. J Affect Disord. 2026 Jul 15;405:121553. doi: 10.1016/j.jad.2026.121553. Epub 2026 Mar 6. Assessing the presence of biasing and non-biasing unblinding in a randomized controlled trial of a home-use tDCS device: An exploratory analysis. Hieronymus F(1), Huneke NTM(2), Månsson D(3), Rehn EM(3)

16.
Safety, tolerability, and preliminary efficacy of seltorexant versus quetiapine extended release as adjunctive therapy in major depressive disorder: a randomized, flexible-dose, 6-month, parallel-group, exploratory study.
The international journal of neuropsychopharmacology 2026 PMID:41795948

3. Int J Neuropsychopharmacol. 2026 Apr 6;29(4):pyag009. doi: 10.1093/ijnp/pyag009. Safety, tolerability, and preliminary efficacy of seltorexant versus quetiapine extended release as adjunctive therapy in major depressive disorder: a randomized, flexible-dose, 6-month, parallel-group, explorator

17.
Safety and efficacy of ravulizumab in patients with NMOSD previously treated with rituximab: A post hoc analysis of the CHAMPION-NMOSD trial.
Multiple sclerosis (Houndmills, Basingstoke, England) 2026 PMID:41782198

28. Mult Scler. 2026 Apr;32(4):396-408. doi: 10.1177/13524585261425076. Epub 2026 Mar 4. Safety and efficacy of ravulizumab in patients with NMOSD previously treated with rituximab: A post hoc analysis of the CHAMPION-NMOSD trial. Bennett JL(1), Bhattacharyya S(2), Zabeti A(3), Levy M(2), de Sèz

18.
Graph neural network-based drug-drug interaction prediction.
Scientific reports 2025 PMID:40830547

5. Sci Rep. 2025 Aug 19;15(1):30340. doi: 10.1038/s41598-025-12936-1. Graph neural network-based drug-drug interaction prediction. Abbas K(1), Hao C(2), Yong X(3), Hasan MK(4), Islam S(5), Rahman AHA(6). Author information: (1)School of Computer Science and Technology, Zhoukou Normal University,

19.
Biased agonism in psychopharmacology: an opportunity to improve efficacy and safety of treatments.
CNS spectrums 2025 PMID:40790531

49. CNS Spectr. 2025 Aug 12;30(1):e63. doi: 10.1017/S109285292510045X. Biased agonism in psychopharmacology: an opportunity to improve efficacy and safety of treatments. Le GH(1)(2)(3), Wong S(1)(2)(4), Bargiota S(5), Jennifer S(6)(7), Lo HKY(8), Orsini D(1)(4), Teopiz K(1)(2)(3), Guillen-Burgos

20.
Enhancing antioxidant and antibacterial activities of Cuminum cyminum, Origanum vulgare, and Salvia officinalis essential oils through a synergistic perspective.
Scientific reports 2025 PMID:40702010

32. Sci Rep. 2025 Jul 23;15(1):26728. doi: 10.1038/s41598-025-10814-4. Enhancing antioxidant and antibacterial activities of Cuminum cyminum, Origanum vulgare, and Salvia officinalis essential oils through a synergistic perspective. Gheisary B(1), Ashrafi-Saeidlou S(2), Hassani A(1), Fattahi M(3

21.
Cognitive effects, pharmacokinetics, and safety of zuranolone administered alone or with alprazolam or ethanol in healthy adults in a phase 1 trial.
Journal of psychopharmacology (Oxford, England) 2024 PMID:39394685

11. J Psychopharmacol. 2024 Dec;38(12):1122-1136. doi: 10.1177/02698811241282777. Epub 2024 Oct 11. Cognitive effects, pharmacokinetics, and safety of zuranolone administered alone or with alprazolam or ethanol in healthy adults in a phase 1 trial. Dunbar J(1), Walling DP(2), Hassman HA(3), Jain

22.
Pharmacokinetics, safety, and efficacy of cedirogant from phase I studies in healthy participants and patients with chronic plaque psoriasis.
Clinical and translational science 2024 PMID:38112262

34. Clin Transl Sci. 2024 Jan;17(1):e13682. doi: 10.1111/cts.13682. Epub 2023 Dec 19. Pharmacokinetics, safety, and efficacy of cedirogant from phase I studies in healthy participants and patients with chronic plaque psoriasis. Mohamed MF(1), Qian Y(1), D'Cunha R(1), Sligh T(2), Ferris LK(3), El

23.
SSRIs differentially modulate the effects of pro-inflammatory stimulation on hippocampal plasticity and memory via sigma 1 receptors and neurosteroids.
Translational psychiatry 2023 PMID:36737431

39. Transl Psychiatry. 2023 Feb 3;13(1):39. doi: 10.1038/s41398-023-02343-3. SSRIs differentially modulate the effects of pro-inflammatory stimulation on hippocampal plasticity and memory via sigma 1 receptors and neurosteroids. Izumi Y(1)(2), Reiersen AM(1)(2), Lenze EJ(1)(2), Mennerick SJ(1)(2)

24.
Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial.
JAMA 2022 PMID:35819423

20. JAMA. 2022 Jul 12;328(2):151-161. doi: 10.1001/jama.2022.9805. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial. Oslin DW(1)(2), Lynch KG(1)(2), Shih MC(3)(4),

25.
Assessment of the latest prescribed drug-related problems.
European review for medical and pharmacological sciences 2022 PMID:35442491

29. Eur Rev Med Pharmacol Sci. 2022 Apr;26(7):2373-2387. doi: 10.26355/eurrev_202204_28467. Assessment of the latest prescribed drug-related problems. Maslub MG(1), Radwan MA, Mikhail MS, Abdalla ZA, Youssef YL, Abdal Hafiz AI, Zain Eldien KM, Sha'aban A. Author information: (1)Pharmacy Practic

26.
Oxysterols Modulate the Acute Effects of Ethanol on Hippocampal N-Methyl-d-Aspartate Receptors, Long-Term Potentiation, and Learning.
The Journal of pharmacology and experimental therapeutics 2021 PMID:33441369

16. J Pharmacol Exp Ther. 2021 Apr;377(1):181-188. doi: 10.1124/jpet.120.000376. Epub 2021 Jan 13. Oxysterols Modulate the Acute Effects of Ethanol on Hippocampal N-Methyl-d-Aspartate Receptors, Long-Term Potentiation, and Learning. Izumi Y(1), Mennerick SJ(1), Doherty JJ(1), Zorumski CF(2). Au

27.
Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA(A) receptor positive allosteric modulator.
Neuropharmacology 2020 PMID:32976892

27. Neuropharmacology. 2020 Dec 15;181:108333. doi: 10.1016/j.neuropharm.2020.108333. Epub 2020 Sep 22. Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA(A) receptor positive allosteric modulator. Althaus AL(1), Ackley MA(2), Belfort GM(2), Gee SM(2), Da

28.
Efficacy and safety of iclepertin for cognitive impairment associated with schizophrenia (CONNEX programme): results from three phase 3 randomised controlled trials.
The lancet. Psychiatry 2025 PMID:41233083

21. Lancet Psychiatry. 2025 Dec;12(12):906-920. doi: 10.1016/S2215-0366(25)00296-2. Efficacy and safety of iclepertin for cognitive impairment associated with schizophrenia (CONNEX programme): results from three phase 3 randomised controlled trials. Keefe RSE(1), Harvey PD(2), Correll CU(3), Fal

29.
Hesitancy and confidence in pediatric COVID-19 vaccination among diverse caregivers of unvaccinated children.
Vaccine 2025 PMID:40472668

33. Vaccine. 2025 Aug 13;61:127245. doi: 10.1016/j.vaccine.2025.127245. Epub 2025 Jun 4. Hesitancy and confidence in pediatric COVID-19 vaccination among diverse caregivers of unvaccinated children. Costello LM(1), Kerns EK(2), McCulloh RJ(2), Roberts JR(3), Blatt DB(4), Tanski SE(5), Smith TR(

30.
Evidence-based guidelines for the pharmacological treatment of migraine, summary version.
Cephalalgia : an international journal of headache 2025 PMID:40277321

22. Cephalalgia. 2025 Apr;45(4):3331024251321500. doi: 10.1177/03331024251321500. Epub 2025 Apr 25. Evidence-based guidelines for the pharmacological treatment of migraine, summary version. Ornello R(1), Caponnetto V(2), Ahmed F(3), Al-Khazali HM(4), Ambrosini A(5), Ashina S(6)(7), Baraldi C(8)

⚠️ 면책 고지

이 정보는 일반 교육 목적이며 의료 진단/처방을 대체하지 않습니다.